NICE: Pembrolizumab for Advanced Oesophageal or Gastro-Oesophageal Junction Cancer

Dawn O'Shea

October 25, 2021

NICE has issued final guidance which recommends pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy as a first-line option for untreated locally advanced unresectable or metastatic oesophageal cancer or HER2‑negative gastro-oesophageal junction adenocarcinoma in patients with PD‑L1-positive tumours and a combined positive score (CPS) of ≥10.

After a review of the evidence, an expert appraisal committee has determined that pembrolizumab meets NICE's criteria to be considered a life-extending treatment at the end of life.

The recommendation is based on findings from the randomised, double-blind, placebo-controlled trial KEYNOTE‑590 (n=749), which compared cisplatin and fluorouracil, with or without pembrolizumab, as first-line treatment for locally advanced unresectable or metastatic oesophageal adenocarcinoma, squamous cell carcinoma or advanced gastro-oesophageal junction adenocarcinoma. The trial recruited participants from 26 countries, including the UK.

For people with a CPS of ≥10, KEYNOTE‑590 reported a median progression-free survival of 7.5 months in the pembrolizumab plus chemotherapy arm and 5.5 months in the placebo plus chemotherapy arm (hazard ratio [HR] 0.51; 95% CI 0.41-0.65; P<.001). The corresponding median overall survival for pembrolizumab plus chemotherapy was 13.5 months and 9.4 months for the placebo plus chemotherapy arm (HR 0.62; 95% CI 0.49-0.78; P<.001).

This article originally appeared on Univadis, part of the Medscape Professional Network.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: